Unité de Catalyse et Chimie du Solide, CNRS UMR 8181, Université Lille Nord de France.
Parasite. 2011 Aug;18(3):207-14. doi: 10.1051/parasite/2011183207.
Ferroquine (FQ, SSR97193) is currently the most advanced organo-metallic drug candidate and about to complete phase II clinical trials as a treatment for uncomplicated malaria. This ferrocene-containing compound is active against both chloroquine-susceptible and chloroquine-resistant Plasmodium falciparum and P. vivax strains and/or isolates. This article focuses on the discovery of FQ, its antimalarial activity, the hypothesis of its mode of action, the current absence of resistance in vitro and recent clinical trials.
铁喹（FQ，SSR97193）是目前最先进的有机金属药物候选物，即将完成 II 期临床试验，作为治疗无并发症疟疾的药物。这种含二茂铁的化合物对氯喹敏感和氯喹耐药的恶性疟原虫和间日疟原虫株和/或分离株均有活性。本文重点介绍了 FQ 的发现、抗疟活性、作用机制假说、目前体外无耐药性以及最近的临床试验。
